| Survivor (n = 182) | Non survivor (n = 52) | P value | ||
---|---|---|---|---|---|
All patients (n = 234) | Empirical | Combination | 31 (17.0%) | 7 (13.5%) | 0.74 |
 | Monotherapy | 78 (42.9%) | 25 (48.1%) |  | |
 | Inappropriate | 31 (17.0%) | 7 (13.5%) |  | |
Targeted | Combination | 36 (19.8%) | 6 (11.5%) | 0.31 | |
 | Monotherapy | 109 (59.9%) | 32 (61.5%) |  | |
 | Inappropriate | 37 (20.3%) | 14 (26.9%) |  | |
Patients with neutropenia (n = 54) | Empirical | Combination | 19 (52.7%) | 4 (22.2%) | 0.001 |
 | Monotherapy | 16 (44.4%) | 7 (38.8%) |  | |
 | Inadequate | 1 (2.7%) | 7 (38.8%) |  | |
Targeted | Combination | 21 (58.3%) | 10 (55.5%) | 0.01 | |
 | Monotherapy | 14 (38.8%) | 3 (16.7%) |  | |
 |  | Inadequate | 1 (2.7%) | 5 (27.7%) |  |